404 related articles for article (PubMed ID: 29194711)
1. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ
Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
5. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression.
Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB
J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
[TBL] [Abstract][Full Text] [Related]
10.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
11. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
[TBL] [Abstract][Full Text] [Related]
12. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
[TBL] [Abstract][Full Text] [Related]
13. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
[TBL] [Abstract][Full Text] [Related]
14. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
16. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
Salem R; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Ibrahim S; Atassi B; Baker T; Gates V; Miller FH; Sato KT; Wang E; Gupta R; Benson AB; Newman SB; Omary RA; Abecassis M; Kulik L
Gastroenterology; 2010 Jan; 138(1):52-64. PubMed ID: 19766639
[TBL] [Abstract][Full Text] [Related]
17. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
[TBL] [Abstract][Full Text] [Related]
18. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
[TBL] [Abstract][Full Text] [Related]
19.
Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.
Memon K; Kulik LM; Lewandowski RJ; Wang E; Wang J; Ryu RK; Hickey R; Vouche M; Baker T; Ganger D; Gates VL; Habib A; Mulcahy MF; Salem R
J Vasc Interv Radiol; 2014 Jul; 25(7):1056-66. PubMed ID: 24613269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]